GlaxoSmithKline Pharmaceuticals launches Trelegy Ellipta for COPD patients

26 Apr 2022 Evaluate

GlaxoSmithKline Pharmaceuticals has launched Trelegy Ellipta for Chronic Obstructive Pulmonary Disease (COPD) patients. Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) is the first once daily single-inhaler triple therapy (SITT) in India for COPD patients.

The product launch comes after the Drugs Controller General of India (DCGI) approved the use of Trelegy Ellipta as maintenance treatment to prevent and relieve symptoms associated with Chronic Obstructive Pulmonary Disease (COPD) in patients aged 18 and above.

GlaxoSmithKline Pharmaceuticals is an Indian subsidiary of GlaxoSmithKline plc. The company business has a broad portfolio of innovative and established medicines, with leadership positions in respiratory and HIV.

Glaxosmithkline Phar Share Price

2468.00 3.10 (0.13%)
29-Dec-2025 09:44 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1721.80
Dr. Reddys Lab 1269.35
Cipla 1513.50
Zydus Lifesciences 909.75
Lupin 2102.95
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×